{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:01:48Z","timestamp":1790337708280,"version":"4.1.0"},"reference-count":25,"publisher":"The Endocrine Society","issue":"11","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy frequently associated with cortisol hypersecretion, which confers substantial morbidity and a worse prognosis. In metastatic ACC, rapid control of Cushing syndrome is essential to allow systemic therapy. Although the block-and-replace strategy using steroidogenesis inhibitors is well established for cortisol control, its potential antineoplastic effects have not been previously reported. We describe 2 patients with metastatic ACC and severe Cushing syndrome treated with block-and-replace using osilodrostat or metyrapone. In both, cortisol normalized rapidly and safely, with marked clinical improvement. Unexpectedly, both experienced significant radiological tumor responses before exposure to effective cytotoxic chemotherapy and before therapeutic mitotane plasma concentrations were achieved. These cases suggest that steroidogenesis inhibition within a block-and-replace strategy may exert a direct or indirect antineoplastic effect in ACC. Although causality cannot be established, the temporal association between cortisol blockade and tumor response is compelling and warrants further prospective and translational investigation.<\/jats:p>","DOI":"10.1210\/jcemcr\/luag262","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:30:41Z","timestamp":1788521441000},"source":"Crossref","is-referenced-by-count":0,"title":["Antineoplastic effect of block-and-replace strategy for managing hypercortisolism caused by adrenal cortical carcinoma"],"prefix":"10.1210","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2356-6511","authenticated-orcid":false,"given":"Davide Lorenzo","family":"Bettini","sequence":"first","affiliation":[{"name":"Medical Oncology, University of Brescia, ASST Spedali Civili Comprehensive Cancer Center , Brescia 25123 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3248-6655","authenticated-orcid":false,"given":"Sara","family":"Rodella","sequence":"additional","affiliation":[{"name":"Medical Oncology, University of Brescia, ASST Spedali Civili Comprehensive Cancer Center , Brescia 25123 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8457-122X","authenticated-orcid":false,"given":"Marta","family":"Lagan\u00e0","sequence":"additional","affiliation":[{"name":"Medical Oncology, University of Brescia, ASST Spedali Civili Comprehensive Cancer Center , Brescia 25123 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8018-588X","authenticated-orcid":false,"given":"Antonella","family":"Turla","sequence":"additional","affiliation":[{"name":"Medical Oncology, University of Brescia, ASST Spedali Civili Comprehensive Cancer Center , Brescia 25123 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3956-0043","authenticated-orcid":false,"given":"Alfredo","family":"Berruti","sequence":"additional","affiliation":[{"name":"Medical Oncology, University of Brescia, ASST Spedali Civili Comprehensive Cancer Center , Brescia 25123 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8962-5020","authenticated-orcid":false,"given":"Deborah","family":"Cosentini","sequence":"additional","affiliation":[{"name":"Medical Oncology, University of Brescia, ASST Spedali Civili Comprehensive Cancer Center , Brescia 25123 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"issue":"11","key":"2026092507131175200_luag262-B1","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1016\/j.ejca.2013.02.034","article-title":"Adrenocortical carcinoma: a population-based study on incidence and survival in The Netherlands since 1993","volume":"49","author":"Kerkhofs","year":"2013","journal-title":"Eur J Cancer"},{"issue":"3","key":"2026092507131175200_luag262-B2","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae012","article-title":"Incidence, treatment, and survival of adrenocortical carcinoma in Denmark 2003-2019","volume":"8","author":"Pedersen","year":"2024","journal-title":"J Endocr Soc"},{"issue":"1","key":"2026092507131175200_luag262-B3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eprac.2023.10.004","article-title":"Incidence and geographical distribution of adrenocortical carcinoma: retrospective analysis of a state cancer registry","volume":"30","author":"Balderrama-Brondani","year":"2024","journal-title":"Endocr Pract"},{"issue":"7","key":"2026092507131175200_luag262-B4","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1210\/jc.2005-2730","article-title":"Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients","volume":"91","author":"Abiven","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026092507131175200_luag262-B5","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.eururo.2013.11.006","article-title":"Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer","volume":"65","author":"Berruti","year":"2014","journal-title":"Eur Urol"},{"issue":"11","key":"2026092507131175200_luag262-B6","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.4158\/DSCR-2020-0567","article-title":"American Association of Clinical Endocrinology Disease State Clinical Review on the evaluation and management of adrenocortical carcinoma in an adult: a practical approach","volume":"26","author":"Kiseljak-Vassiliades","year":"2020","journal-title":"Endocr Pract"},{"issue":"6","key":"2026092507131175200_luag262-B7","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1210\/clinem\/dgac691","article-title":"Efficacy and safety of osilodrostat in paraneoplastic cushing syndrome: a real-world multicenter study in France","volume":"108","author":"Dormoy","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026092507131175200_luag262-B8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1210\/endrev\/bnaf042","article-title":"Update and practical recommendations for the use of medical treatment of Cushing\u00b4s syndrome","volume":"47","author":"Araujo-Castro","year":"2026","journal-title":"Endocr Rev"},{"issue":"9","key":"2026092507131175200_luag262-B9","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","article-title":"Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase","volume":"8","author":"Pivonello","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2026092507131175200_luag262-B10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s12020-017-1428-9","article-title":"Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma","volume":"61","author":"Claps","year":"2018","journal-title":"Endocrine"},{"issue":"e3","key":"2026092507131175200_luag262-B11","doi-asserted-by":"crossref","first-page":"e971","DOI":"10.1136\/spcare-2023-004233","article-title":"Efficacy of metyrapone for symptoms of adrenocortical carcinoma","volume":"13","author":"Okuda","year":"2024","journal-title":"BMJ Support Palliat Care"},{"issue":"2","key":"2026092507131175200_luag262-B12","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ecl.2018.02.003","article-title":"Adrenocortical carcinoma with hypercortisolism","volume":"47","author":"Puglisi","year":"2018","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"23","key":"2026092507131175200_luag262-B13","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"2026092507131175200_luag262-B14","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1530\/EJE-18-0450","article-title":"Influence of hormonal functional status on survival in adrenocortical carcinoma: systematic review and meta-analysis","volume":"179","author":"Vanbrabant","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026092507131175200_luag262-B15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.surg.2023.04.070","article-title":"The effect of hormonal secretion on survival in adrenocortical carcinoma: a multi-center study","volume":"175","author":"Sada","year":"2024","journal-title":"Surgery"},{"issue":"4","key":"2026092507131175200_luag262-B16","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1210\/clinem\/dgaf552","article-title":"Osilodrostat-associated adrenal gland shrinkage: a case series of patients with ACTH-dependent Cushing's syndrome","volume":"111","author":"Varlamov","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026092507131175200_luag262-B17","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2026092507131175200_luag262-B18","doi-asserted-by":"crossref","first-page":"R207","DOI":"10.1530\/EJE-20-1309","article-title":"MANAGEMENT OF ENDOCRINE DISEASE: cardiovascular risk assessment, thromboembolism, and infection prevention in Cushing's syndrome: a practical approach","volume":"184","author":"Varlamov","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"2026092507131175200_luag262-B19","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1210\/jc.2016-2414","article-title":"Antisecretive and antitumor activity of abiraterone acetate in human adrenocortical cancer: a preclinical study","volume":"101","author":"Fiorentini","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026092507131175200_luag262-B20","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1210\/jc.2017-02591","article-title":"Mitotane monotherapy in patients with advanced adrenocortical carcinoma","volume":"103","author":"Megerle","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026092507131175200_luag262-B21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000469","article-title":"Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma","volume":"8","author":"Landwehr","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"4","key":"2026092507131175200_luag262-B22","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nri.2017.1","article-title":"Immune regulation by glucocorticoids","volume":"17","author":"Cain","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"2026092507131175200_luag262-B23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2024.106462","article-title":"Histopathological analysis of tumor microenvironment in adrenocortical carcinoma: possible effects of in situ disorganized glucocorticoid production on tumor immunity","volume":"238","author":"Ishikawa","year":"2024","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"11","key":"2026092507131175200_luag262-B24","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1210\/en.2019-00152","article-title":"Adrenocortical carcinoma xenograft in zebrafish embryos as a model to study the in vivo cytotoxicity of abiraterone acetate","volume":"160","author":"Gianoncelli","year":"2019","journal-title":"Endocrinology"},{"issue":"3","key":"2026092507131175200_luag262-B25","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1530\/EJE-13-0242","article-title":"Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection","volume":"169","author":"Terzolo","year":"2013","journal-title":"Eur J Endocrinol"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/11\/luag262\/71394824\/luag262.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/11\/luag262\/71394824\/luag262.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:14:06Z","timestamp":1790334846000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luag262\/8835637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,9,25]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luag262","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,9,25]]},"article-number":"luag262"}}